Cyclo Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
10-Q: Cyclo Therapeutics Reports Q3 2024 Results Amidst Proposed Merger and Nasdaq Compliance Challenges
Cyclo Therapeutics reported a net loss for Q3 2024, a decrease in revenue, and is navigating a proposed merger with Rafael Holdings while addressing Nasdaq listing compliance issues.
Cyclo Therapeutics announced its Q2 2024 financial results, highlighted by the completion of enrollment in its pivotal Phase III clinical trial for Niemann-Pick Type C disease (NPC) and a net loss of $10.3 million for the first six months of 2024.
Cyclo Therapeutics saw a 33% increase in revenue and a reduced net loss in the first quarter of 2024 compared to the same period last year, while also highlighting ongoing clinical trials and financial challenges.